TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00215995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: As outlined in Detailed Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: As outlined in Detailed Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD 1839
Description: As outlined in Detailed Description
Study: NCT00636675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falls QI
Description: Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~1. In-House Falls Coordinator training on content and falls processes.~2. Case-based modules about fall prevention and tailored for various team members.~3. Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~4. Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~5. Toolbox: Handbook of useful measures and worksheets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~1. In-class learning sessions introduce interaction strategies.~2. Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~3. Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role.
Study: NCT03561103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client-Centered Representative Payee
Description: CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client-Centered Representative Payee
Description: CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
Study: NCT01133899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: guanidinoacetic acid
Description: 2.4 grams of guanidinoacetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GAA-4
Description: 4.8 grams of guanidinoacetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GAA-1
Description: 1.2 grams of guanidinoacetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: celulose
Study: NCT01575106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat pain applied using TSA or CHEPS
Description: TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
Study: NCT00932204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)
Description: For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)
Description: For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
Study: NCT04229433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285 tablet
Description: Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285 tablet
Description: Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
Study: NCT03228472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive brain stimulation
Description: TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Description: Placebo treatment
Study: NCT00657813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNI-330 as a brain SPECT tracer of Beta-Amyloid
Description: Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
Study: NCT02889406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Description: motivational interviewing schema
Study: NCT01102348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP-uP Protocol
Description: Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
Study: NCT04146779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Video
Description: A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Video
Description: A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posture and Strengthening Video
Description: The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posture and Strengthening Video
Description: The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Video
Description: The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Video
Description: The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Work Video
Description: The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Work Video
Description: The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction Survey
Description: Participants will complete a questionnaire addressing satisfaction with the yoga program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction Survey
Description: Participants will complete a questionnaire addressing satisfaction with the yoga program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Yoga Session
Description: Instructor guided yoga session twice a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Yoga Instructions
Description: Introduction to Yoga and Yoga poses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Yoga Instructions
Description: Introduction to Yoga and Yoga poses
Study: NCT04203745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative Fractional Diode Laser
Description: The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
Study: NCT05560256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary/Journal
Description: Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
Study: NCT01764542

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy and biopsy
Description: Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
Study: NCT03649282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC
Description: HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC
Description: HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
Study: NCT03384862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
Study: NCT03649282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP
Description: NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP
Description: NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
Study: NCT00616915

Intervention type: DRUG
Group type: OTHER
Intervention: Wellbutrin XL
Description: Wellbutrin XL 300mg daily
Study: NCT00003765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study: NCT00478933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator, Dual Chamber ; Implantable
Description: Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling
Study: NCT02865018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine
Study: NCT01456650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening.
Study: NCT01520311

Intervention type: DEVICE
Group type: OTHER
Intervention: eSVS Mesh
Description: Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
Study: NCT03495089

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dermal electrochemical conductance (DEC)
Description: The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dermal electrochemical conductance (DEC)
Description: The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dermal electrochemical conductance (DEC)
Description: The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monofilament testing
Description: Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monofilament testing
Description: Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monofilament testing
Description: Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
Study: NCT03241901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine Tab 20-120mg
Description: Artemether-Lumefantrine Tablet 20-120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine Tab 20-120mg
Description: Artemether-Lumefantrine Tablet 20-120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate 0.25 mg/kg
Description: Primaquine Phosphate 0.25 mg/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Aqueous solution prepared to mimic the taste of the intervention drug.
Study: NCT04353284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally, 4 times daily, for 7 days.
Study: NCT01482585

Intervention type: OTHER
Intervention: CT, PET, copy number alteration
Description: Duel-energy CT, PET, copy number alteration
Study: NCT03073668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior pericardiotomy
Description: The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
Study: NCT03677596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin-dose level 2
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotuzumab ozogamicin-dose level 1
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
Study: NCT00768326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks
Study: NCT05568108

Intervention type: PROCEDURE
Intervention: masseteric nerve to central branch facial nerve
Description: masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)

Intervention type: PROCEDURE
Intervention: Masseteric nerve to free functioning muscle transfer
Description: Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
Study: NCT02539420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP treatment
Description: Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP treatment
Description: Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
Study: NCT01735279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
Study: NCT00674583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' meningococcal vaccine GSK134612
Description: Intramuscular administration, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: Intramuscular administration, 1 dose
Study: NCT00122681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™-based investigational formulation
Description: Intramuscular injection, 3 doses
Study: NCT00897806

Intervention type: GENETIC
Intervention: Microarray analysis

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Study: NCT02879227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f